First-in-Human Phase I Trial of a ROR1 Targeting Bispecific T Cell Engager (NVG-111) in Combination with Ibrutinib or As Monotherapy in Subjects with Relapsed Refractory Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL)

Saved in:
Bibliographic Details
Published inBlood Vol. 140; no. Supplement 1; pp. 4162 - 4163
Main Authors Townsend, William, Leong, Sarah, Tucker, David, Pottinger, Bryson, Paneesha, Shankara, El-Sharkawi, Dima, Eyre, Toby A., Batten, Toby, Shah, Mittal, Cook, Sarah, Granger, David, O'Donovan, Kieran, Nathwani, Amit C., Jasani, Parag
Format Journal Article
LanguageEnglish
Published Elsevier Inc 15.11.2022
Online AccessGet full text

Cover

More Information
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2022-169658